.png)
Just 3.4% of oncology drugs in clinical trials make it to market, and only 50% of late-stage cancer patients benefit from their first treatment. Katie-Rose Skelly's company, Known Medicine, hopes to shrink this number using machine learning to predict patient outcomes -- an idea that's raised $7.2 million in seed funding from investors.
